Vardi J, Glaubman H, Rabey J M, Streifler M
J Neurol. 1978 Apr 14;218(1):35-42. doi: 10.1007/BF00314716.
Six patients with Parkinson's disease developed nocturnal myoclonic attacks after prolongued treatment with L-Dopa which were electroencephalographically recorded. These symptoms persisted after treatment with 2 bromo-alpha-ergocryptin (Bromocryptin), a dopamine receptor agonist, which was substituted for L-Dopa. Bromocryptin is known to have no pre- or postsynaptic effect on serotonin metabolism. It is proposed that these myoclonic phenomena are the expression of the hypersensitivity of denervated catecholamine receptors in the brainstem to the stimulation of L-Dopa and Bromocryptin. This thesis differs with previous suggestions that serotonin plays a major role in the genesis of myoclonic seizures in Parkinsonian patients treated with L-Dopa.
六名帕金森病患者在长期使用左旋多巴治疗后出现夜间肌阵挛发作，并进行了脑电图记录。在用多巴胺受体激动剂2-溴-α-麦角隐亭（溴隐亭）替代左旋多巴治疗后，这些症状仍持续存在。已知溴隐亭对5-羟色胺代谢没有突触前或突触后作用。有人提出，这些肌阵挛现象是脑干中去神经支配的儿茶酚胺受体对左旋多巴和溴隐亭刺激超敏反应的表现。这一论点与之前认为5-羟色胺在接受左旋多巴治疗的帕金森病患者肌阵挛发作的发生中起主要作用的观点不同。
